Distributor concentration
A small number of distributors account for most net revenue, so order timing and purchasing patterns can swing results.
- Scope
- Three U.S. and six non-U.S. distributors represented about 77% of net revenues.
- Materiality
- high
KORU Medical Systems, Inc.
KORU Medical Systems develops, manufactures, and commercializes portable large-volume subcutaneous infusion solutions used to deliver drugs under the FREEDOM Infusion System brand. Its products are designed for home and specialty-care administration of therapies such as immunoglobulin for PIDD and CIDP, and the company also supports pharma clinical trials and customization work for biopharmaceutical customers.
−5,3 %
62,3 %
−6,4 %
+22,2 %
2.44
1.99
| % | |
|---|---|
| Mechanical infusion systems | 55% Portable syringe drivers and related devices used to infuse subcutaneous therapies. |
| Consumables | 35% Needle sets and tubing used with the FREEDOM System for recurring patient use. |
| Pharma services and clinical trials | 10% Product supply and support for feasibility studies and clinical trial programs. |
KORU sells mainly to specialty pharmacies, home infusion providers, pharmaceutical companies, and medical device...
- Specialty pharmaciesprimary
Buy drivers, tubing, and needle sets for patients receiving immunoglobulin at home; they value one-stop purchasing and inventory management.
- Home infusion providersprimary
Purchase the FREEDOM System for subcutaneous drug administration in home-care settings where portability and patient convenience matter.
- Medical device distributorsprimary
Resell KORU products and account for a large share of revenue; they matter because purchasing patterns can swing quarterly results.
- Pharmaceutical and biopharma companiessecondary
Buy product supply and engineering support for feasibility studies, clinical trials, and commercialization readiness.
- Hospitals and ambulatory service providerssecondary
Use the system for subcutaneous drug delivery in clinical settings and outpatient care.
KORU’s core business is split between domestic core revenue, which includes the U.S. and Canada, and international core...
- •Domestic core covers the U.S. and Canada
- •International core provides meaningful non-U.S. growth
- •Mahwah, New Jersey is the main manufacturing site
- •Nicaragua contract manufacturing supplies consumables
- •Distributor concentration makes regional execution important
KORU’s strategy centers on expanding adoption of the FREEDOM System in subcutaneous drug delivery while broadening its...
01
Broaden distribution and reduce concentrationshort-term
A few distributors drive most revenue, so expanding channels lowers dependency and improves resilience.
02
International expansionmedium-term
Non-U.S. growth can diversify the business and increase the installed base of the FREEDOM System.
03
Product innovation and clinical customizationmedium-term
New devices and services help defend against competition and support biopharma commercialization.
KORU is exposed to customer concentration, distributor dependence, and competitive pressure in a medical-device market...
Manufacturing and supply chain disruption
Production is split between Mahwah and Nicaragua, and any site outage or border/logistics issue could delay shipments.
- Scope
- Needle sets and tubing rely on contract manufacturing in Nicaragua.
- Materiality
- high
Regulatory and reimbursement changes
Demand depends on FDA clearance, payer coverage, and reimbursement for the therapies delivered with the system.
- Scope
- Subcutaneous drug delivery and immunoglobulin therapy markets.
- Materiality
- high
Competitive and pricing pressure
Consolidation among medical device buyers and suppliers can increase bargaining power and force price reductions.
- Scope
- Specialty pharmacy, distributor, and healthcare-system channels.
- Materiality
- medium
Technology obsolescence
If KORU fails to introduce new products or keep pace with infusion technology, customers may switch to alternatives.
- Scope
- Mechanical infusion systems and accessories.
- Materiality
- medium
Revenue recognition at shipment
Quarterly comparability
Warranty accruals
Gross margin and operating expense
Inventory valuation
Working capital and cost of sales
Liquidity and financing assumptions
Capital structure and dilution risk
: 28.4.2026